Metagenomi Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Metagenomi, Inc. (MGX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021
Period EndingDec 2024Dec 2023Dec 2022Dec 2021
Operating Activities
Net Income-78.06-68.26-43.59-21.44
Depreciation & Amortization5.414.211.730.39
Stock Based Compensation16.206.921.960.38
Change in Working Capital-59.67-26.4369.4946.26
Change in Accounts Receivable1.19-1.18-1.270.00
Change in Accounts Payable-1.11-0.082.260.70
Change in Other Working Capital-59.763.401.081.24
Other Operating Activities7.043.471.081.24
Net Cash from Operating Activities-109.07-91.4129.7224.26
Investing Activities
Capital Expenditures-3.11-9.81-13.98-2.90
Purchases of Investments-306.4255.55-214.85-71.41
Sales/Maturities of Investments221.38263.64106.630.00
Net Cash from Investing Activities-88.1645.73-122.20-74.32
Financing Activities
Common Stock Issued84.010.000.000.00
Other Financing Activities0.00-3.280.000.00
Net Cash from Financing Activities84.011.01239.5939.92
Summary
Net Change in Cash-113.22-44.66147.12-10.14
Cash at Beginning of Period145.85190.5143.4053.53
Cash at End of Period32.63145.85190.5143.40
Free Cash Flow-112.19-101.2215.7521.35
Supplemental Disclosures
Interest Paid0.000.002.161.45
Income Taxes Paid3.512.250.000.00